Aceso Therapeutics

Aceso Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation small molecule therapies for oncology. The company specializes in targeting the MAPK signaling pathway, a critical driver in many types of cancer, including lung, colorectal, and pancreatic malignancies. Its lead program, ACE-8622, is a highly selective ERK1/2 inhibitor currently in Phase 1 clinical development. Aceso aims to overcome resistance mechanisms in cancer treatment through its pipeline of inhibitors targeting SHP2, SOS1, and other key nodes in oncogenic pathways. The company maintains operations in both Shanghai and San Diego, leveraging a global R&D approach to address unmet medical needs in cancer care. Founded by industry veterans, Aceso is backed by prominent life science investors such as Qiming Venture Partners and Lilly Asia Ventures.